Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Pirenzepine for Prevention of Chemotherapy Induced Peripheral Neuropathy
NCT05488873Phase 2Active, not recruiting
- Sponsor
- WinSanTor Inc.
- Start
- Nov 2022
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirenzepine in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by WinSanTor Inc.. Started Nov 2022; status: active, not recruiting.
02
Drugs
pirenzepine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05488873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05488873.